Aims and objectives of this presentation
This session will focus on new management options for renal cell cancer in the post-TKI era.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

763
Clinical impact of the dose modification of second-line targeted therapy for patients with metastatic renal cell carcinoma
By: Shirotake S.1, Yasumizu Y.1, Tanaka N.2, Mizuno R.2, Ito Y.2, Miyazaki Y.2, Masunaga A.3, Ito K.3, Hagiwara M.3, Asano T.1, Oya M.4, Oyama M.1
Institutes: 1Saitama International Medical Center, Dept. of Urology, Hidaka City, Saitama, Japan, 2Keio University School of Medicine, Dept. of Urology, Shinjuku, Tokyo, Japan, 3National Defense Medical College, Dept. of Urology, Tokorozawa, Saitama, Japan, 4Ichikawa General Hospital, Tokyo Dental College, Dept. of Urology, Ichikawa, Chiba, Japan

752
Prognostic significance of nephrectomy in patients with metastatic renal cell carcinoma treated with first-line systemic therapy: A 10-year retrospective analysis according to MSKCC and Heng risk criteria
By: Joung J.Y.1, Seo H.K.1, Kim S.H.1, Lee K.H.1, Chung J.1, Kwon W-A.2
Institutes: 1National Cancer Center, Dept. of Urology, center for Prostate Cancer, Goyang-Si, South Korea, 2School of Medicine, Institute of Wonkwang Medical Science, Wonkwang University Sanbon Hospital, Dept. of Urology, Gunpo, Gyeonggi-Do, South Korea

*753
Dynamic contrast-enhanced CT predicts response to antiangiogenic treatment in patients with metastatic renal cell cancer: Early results
By: Staehler M.1, Sterzik A.2, Casuscelli J.1, Karpitschka M.2, Roosen A.1, Spek A.1, Ziegelmüller B.1, Stief C.1, Reiser M.2, Graser A.2
Institutes: 1LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, 2LMU-Klinikum der Universität München, Dept. of Radiology, Munich, Germany

*754
Trends in cytoreductive nephrectomy in New South Wales, Australia
By: Beattie K.1, Patel M.I.1, Bang A.1, Smith D.P.2
Institutes: Westmead Hospital, Dept. of Urology, Sydney, Australia, 2Cancer Council, Cancer Research Division, Sydney, Australia

*755
Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival
By: Meyer C.1, Trinh Q-D.1, Vetterlein M.1, Löppenberg B.1, Hanske J.1, Leow J.1, Sammon J.2, Abdollahi F.3, Menon M.3, Kibel A.1, Chang S.1, Choueiri T.3, Sun M.1
Institutes: 1Brigham and Women's Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America, 3Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

*756
Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma
Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Final long-term results from EXIST-2


Institutes: Cincinnati Children's Hospital Medical Center, Dept. of Neurology, Cincinnati, United States of America, National Tuberculosis and Lung Diseases Research Institute, Dept. of Lung Disease, Warsaw, Poland, University Medical Center Utrecht, Dept. of Radiology and Nuclear Medicine, Utrecht, The Netherlands, Schlumberger Moscow Research Center, Moscow Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russia, Minnesota Epilepsy Group, Dept. of Epilepsy, Saint Paul, United States of America, Klinikverbund Kempten-Oberalpilg, Facharzt F. Innere Medizin, Nephrologie, Kempten, Germany, Royal Sussex County Hospital, The Trafford Dept of Renal Medicine, Brighton, United Kingdom, Charite-Universitätsmedizin, Berlin, Germany, University of Cape Town, Faculty of Health Sciences, Cape Town, South Africa, Novartis Pharma MCH, Dept. of Oncology, Rueil-Malmaison, France, University of Tennessee Health Science Center, St. Jude Children's Research Hospital and Le Bonheur Children's Hospital, Memphis, United States of America

Comprehensive analysis and validation of contemporary survival prognosticators in patients with metastatic renal cell carcinoma treated with targeted therapy


Institutes: Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, National University College of Medicine, Dept. of Urology, Busan, South Korea

Alternative treatment with every other day dosing of sunitinib for patients with metastatic renal cell carcinoma: Efficacy and safety

By: Ohba K., Miyata Y., Asai A., Matsu T., Sakai H.

Institutes: Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan

Prognostic significance of early CRP response for metastatic renal cell carcinoma treated with tyrosine kinase inhibitor


Institutes: Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, JA Toride Medical Center, Dept. of Urology, Ibaraki, Japan, Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

Results of a phase I/II study in metastatic renal cell carcinoma patients treated with an adjuvant HLA personalized peptide vaccine after resection of metastases and comparison to a contemporary cohort of patients with mRCC


Institutes: University of Tübingen, Dept. of Urology, Tübingen, Germany, University of Tübingen, Dept. of Immunology, Tübingen, Germany
10:00 - 10:07

**Summary and context**

J.P. Bedke, Tübingen (DE)